Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by LPL Financial LLC

LPL Financial LLC raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 17.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,432 shares of the biopharmaceutical company’s stock after acquiring an additional 35,429 shares during the quarter. LPL Financial LLC owned approximately 0.20% of Halozyme Therapeutics worth $15,470,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. Bessemer Group Inc. grew its holdings in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 207 shares during the period. Park Place Capital Corp grew its holdings in Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 182 shares during the period. UMB Bank n.a. grew its holdings in Halozyme Therapeutics by 267.4% in the first quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 960 shares during the period. Finally, CWM LLC grew its holdings in Halozyme Therapeutics by 46.3% in the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 438 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Trading Up 2.5%

NASDAQ HALO opened at $62.33 on Thursday. The company’s fifty day simple moving average is $55.69 and its 200-day simple moving average is $57.83. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $70.50. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13. The stock has a market cap of $7.68 billion, a P/E ratio of 14.26, a PEG ratio of 0.41 and a beta of 1.17.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 142.12%. The business’s revenue was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.91 earnings per share. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on HALO shares. HC Wainwright boosted their target price on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research report on Wednesday. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 7th. Leerink Partners cut shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research report on Tuesday, May 13th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $58.00 to $60.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $66.10.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares in the company, valued at approximately $41,403,763.17. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 60,000 shares of company stock valued at $3,262,400 in the last three months. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.